Jean François Plucker

Cofounder - CEO

About

Through my various professional activities in Intellectual Property and in Business, I have developed a broad economic, political, and cultural perspective. In a constantly changing world, I believe that strong values and a clear sense of purpose will be essential to shaping the future.More recently, I have cofounded several biotechnology startups focused on developing treatments for inflammation, a major cause of acute and chronic pain. These projects combine strong economic potential with meaningful human impact.

Country

Belgium

City

La Hulpe

Industry

Biotechnology

Skill

Patent, Intellectual Property, Intellectuel Property Law, Patent Law, Licensing, Trademarks, Trademark Infringement, Legal Advice, Diabetic Neuropathic Peripheral Pain (DPNP), Neuralgia of the trigeminocervical complex, Migraine, Ischemic Stroke, Chronic Inflammatory Bowel Disease (IBD), Charcot-Marie-Tooth disease (CMT), Disruptive Technologies, Technological Innovation, Biotechnology, Research and Development (R&D), Life Science Industry

Experience

Cofounder - CEO

VALEDYN

2026-2 - Present · 8 mos

San Antonio, TX

VALEDYN Inc. is developing a transformational systems-based intravenous therapy for early and sustained shock stabilization for critical conditions such as sepsis, severe burns, trauma... to extend survivability in austere combat environments as well as in critical care settings.

Cofounder & Associate Director

YNIOS PHARMA

2022-3 - Present · 4 yrs 7 mos

Verlaine

YNIOS PHARMA is Belgian Biotech developing TA64, an innovative intravenous drug designed to modulate inflammation, protect cells, and restore tissue balance in critical care settings. TA64 is currently in preclinical development. The company’s primary goal is to develop TA64 for Septic Shock as its lead indication, with plans to expand its use across multiple ICU-related conditions that share similar pathological mechanisms. In its development process, YNIOS PHARMA also envisions military applications for TA64 as an early treatment initiated immediately for any heavy battlefield injuries.

Founder & Associate Director

OLYS Pharma

2020-1 - Present · 6 yrs 9 mos

Verlaine, Région wallonne, Belgique

Biotech Pharma - Preclinical: peripheral neuropathic pain & chronic nociceptive pain

Président

Kirkpatrick

1986-1 - Present · 40 yrs 9 mos

Brussels

The Intellectual Property firm KIRKPATRICK is a leading IP consultancy firm based in Belgium since 1852. With a team of legal, scientific and technical experts in Patents, Trademarks, and contracts in IP assets transfers, the firm brings strategic value to innovations of established corporations as well as of young starters.